肾透明细胞癌
转移
生物
癌症研究
微阵列分析技术
基因表达谱
肾细胞癌
癌症
日历年61
基因
病理
微阵列
免疫染色
下调和上调
转移抑制基因
癌
基因表达
医学
免疫组织化学
免疫学
遗传学
受体
生长因子
CTGF公司
作者
Xiaojie Tan,Yujia Zhai,Wenjun Chang,Jianguo Hou,Songqin He,Liping Lin,Yongwei Yu,Danfeng Xu,Jianru Xiao,Liye Ma,Guoping Wang,Ting-hu CAO,Guangwen Cao
摘要
Metastatic clear-cell renal-cell carcinoma (ccRCC) has a poor prognosis and unpredictable course, and there are no molecular markers that reliably predict ccRCC metastasis. In this study, ccRCC specimens from 84 patients were directly cultured in vitro. Primary cultures from 38 of 94 specimens contained more than 90% tumor cells at the fourth passage. After identification by immunostaining, the primary cultures of metastatic and nonmetastatic ccRCC specimens from the age- and gender-matched patients were subjected to cDNA microarray assays. A total of 842 differentially expressed genes with a FDR (false discovery rate) of 4.79% were identified. Pathway analysis and co-occurrence with "cancer", "metastasis" and "invasion" in the literature annotations functionally enriched the 842 genes and provided an indication of the reliability of our microarray assays. Novel genes associated with metastasis were selected based on protein-protein interactions between 205 differentially expressed genes that co-occurred with "metastasis" and those that did not co-occur with "metastasis" on Medline, and the results of co-expression analysis between the co-occurred genes and unpublished genes. FSTL1, AV722783, SLC15A1, DDX17, ORC2L and PKMYT1 were found to be potential ccRCC metastasis-associated novel genes, according to expression patterns in cultures and tumor tissues. Interestingly, the upregulated genes (CAV1, PKMYT1 and ORC2L) were also upregulated and the downregulated genes (FSTL1, GSTM3, CYR61, SLC15A1 and AV722783) were also downregulated in the primary ccRCC specimens compared with expression in adjacent renal tissues in 37 patients. This study has identified new candidate biomarkers and targets for the early diagnosis and treatment of ccRCC metastasis.
科研通智能强力驱动
Strongly Powered by AbleSci AI